Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That

Nobel Prize–winning CRISPR pioneer and CEND affiliate Jennifer Doudna is aiming to overcome the commercial hurdles that have slowed gene-editing technologies from reaching patients and broader markets. In a new plan featured in Forbes, Doudna outlines a bold effort to build funding, infrastructure, and support systems to help translate foundational CRISPR research into widely available therapies and applications, underscoring her ongoing influence on the field’s future. Find the fully story here.